Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study

Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity. Polymorphism of the dihydropyrimidine dehydrogenase (DPYD) gene may reduce DPD function, the main enzyme responsible for the metabolism of fluoropyrimidines. This leads to drug accumulation and to an increased risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Soria-Chacartegui, Paula, Villapalos-García, Gonzalo, López-Fernández, Luis A., Navares-Gómez, Marcos, Mejía-Abril, Gina, Abad-Santos, Francisco, Zubiaur, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707980/
https://www.ncbi.nlm.nih.gov/pubmed/34959317
http://dx.doi.org/10.3390/pharmaceutics13122036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707980/
https://www.ncbi.nlm.nih.gov/pubmed/34959317
http://dx.doi.org/10.3390/pharmaceutics13122036

Ejemplares similares